Abstract 5187
Background
The practice of oncology is challenging, especially when dealing with terminally ill patients and end of life. This is not without an emotional impact on oncologists, with potential negative effect on patient care and personal lives. We aimed to outline the main factors that makes of patients’ death an emotionally difficult experience, and to identify practical coping strategies.
Methods
An online survey was completed by 128 oncologists from three North African countries and France, on March-April 2019. All surveys were anonymous and confidential. The questionnaire included socio-demographic information, and sections about patients’ death and coping strategies.
Results
Most respondents were female (83.5%) and young oncologists (20-40 years-old), with less than 10 years professional experience (85.3%), but seeing more than 50 patients per week, and experiencing 0-2 deaths per month. They were mostly from Tunisia (n = 99), Morocco (n = 25), Algeria (n = 2) and France (n = 2). The majority was medical oncologists (57.9%), then radiation oncologists (29.4%). More than two-thirds of the oncologists reported that young age, long-term relationship and family denial towards the prognosis were the main factors making death or therapeutic failure announcement the most difficult. Unexpected evolution leading to death, and the non-access to more effective treatment in our countries had an emotional impact on 70% of the oncologists. A variety of coping strategies was identified: mainly peer support from colleagues and/or family and friends (53.5%), practicing hobbies (39.4%), seeking support in praying and faith (26.3%). Addictive behavior and/or medications were reported in 9.1%, significantly in single respondents (p 0.051). A majority (n = 83) reported a change in their character noticed by their families since the practice of oncology. The oncologists expressed becoming better able to set priorities (48%), more humble and human (61.4%) and motivated to improve their quality of health care (33.9%).
Conclusions
Dealing with patients’ death and confronting therapeutic failure have obviously an effect on oncologists’ personal life. We need to be aware of this issue, and to propose different coping strategies and interventions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4925 - Prognostic role of CD73 in metastatic Non Small Cell Lung Cancer according to the presence of driver alterations
Presenter: Giulia Galli
Session: Poster Display session 1
Resources:
Abstract
785 - JAK-STAT inhibitor overcomes interferon γ-reduced, NK cell-mediated cytotoxicity in non-small-cell lung cancer cells
Presenter: Riki Okita
Session: Poster Display session 1
Resources:
Abstract
2326 - Low LATS2 expression is associated with poor prognosis in non small cell lung cancer
Presenter: Si-hyong Jang
Session: Poster Display session 1
Resources:
Abstract
5960 - Application of ESCAT and OncoKB scales in Liquid biopsy (LB) in Advanced NSCLC patients (pts): Is it feasible and reliable?
Presenter: Michael McCusker
Session: Poster Display session 1
Resources:
Abstract
4855 - IDH1R132H mutation induces a less aggressive phenotype of glioma cells and affects the radiosensitivity by interacting with Wnt/β-catenin signaling
Presenter: Xuetao Han
Session: Poster Display session 1
Resources:
Abstract
2641 - Impact of Angiopoietin-2 on glioblastoma response to combined chemo-radiotherapy
Presenter: Charly Helaine
Session: Poster Display session 1
Resources:
Abstract
5743 - The Discovery of RNA-aptamers That Selectively Bind and Inhibit Glioblastoma Stem Cells by targeting EphA2
Presenter: Alessandra Affinito
Session: Poster Display session 1
Resources:
Abstract
4160 - Impact of tumor reoxygenation by nanoparticles on Tumor Associated Macrophages (TAMs)
Presenter: Aurélie Ferré
Session: Poster Display session 1
Resources:
Abstract
2474 - Prognostic significance of c-Rel/p50 heterodimer in the tumor microenvironment of uveal melanoma
Presenter: Seema Kashyap
Session: Poster Display session 1
Resources:
Abstract
1769 - Synergistic role of BAP1 and DNA damage response pathway in uveal melanoma and its prognostic significance.
Presenter: JAYANTI JHA
Session: Poster Display session 1
Resources:
Abstract